INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE);UNIVERSITÉ DE LIMOGES;CENTRE HOSPITALIER RÉGIONAL UNIVERSITAIRE DE LIMOGES
发明人:
Aurélie PREMAUD,Annick ROUSSEAU,Marie ESSIG
申请号：
US16615905
公开号：
US20200170580A1
申请日:
2018.05.23
申请国别(地区):
US
年份:
2020
代理人:
摘要：
The present invention relates to methods for assessing graft failure risk. Many predictive models of graft survival based on large panels of data collected exist but a limitation of these models is that they do not take into account the onset of adverse events over time, which modify graft outcome. The inventors developed a conditional and adjustable score, taking into account onset of emerging risks over time such as development of dnDSA, for prediction of graft failure (AdGFS) up to 10 years post-transplantation in 664 kidney transplant patients. AdGFS was externally validated and calibrated in 896 kidney transplant patients. In particular, the present invention relates to a method of assessing graft failure risk in a subject by measuring several factors: serum creatinine concentration, de novo donor-specific anti-HLA antibodies, pretransplant non donor-specific anti-HLA antibodies, acute rejection, age, proteinuria longitudinal serum creatinine cluster.
